Market Technicals Simplified: Inovio Pharma, Sequenom, Nektar Therapeutics, and Discovery Laboratories PR Newswire LONDON, January 16, 2014 LONDON, January 16, 2014 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. On Wednesday, January 15, 2014, the U.S. equity market advanced, as the S&P 500 ended the day at1,848.38, up 0.52%; the Dow Jones Industrial Average closed at 16,481.94, up 0.66%; and the NASDAQ Composite finished at4,214.88, up 0.76%. The S&P 500 Health Care Sector Index edged 0.14% lower to close the session at 659.40; and the same has gained 6.17% in the last one month and 11.06% in the previous three months, outperforming the S&P 500, which has gained 4.12% and 8.85% during the respective periods. The major movers in the Health Care Sector includedInovio Pharmaceuticals Inc. (NYSE MKT: INO), Sequenom Inc. (NASDAQ: SQNM), Nektar Therapeutics (NASDAQ: NKTR), and Discovery Laboratories Inc. (NASDAQ: DSCO). All these companies are tracked by AAAResearchReports.com. Free technical research on INO, SQNM, NKTR, and DSCO can be downloaded upon signing up at: http://www.aaaresearchreports.com/register/ Inovio Pharmaceuticals Inc.'s stock edged 0.41% lower on Wednesday, even as the broader market posted gains. The company's shares ended the day at $2.44, after oscillating between $2.40 and $2.50 during the trading session. A total of 2.42 million shares were traded, which is below the daily average volume 4.30 million. Despite Wednesday's decline, the company's shares have surged 28.42% in the previous three months and 23.23% in the last one month, outperforming the S&P 500, which has gained 8.85% and 4.12% during the respective periods. Moreover, Inovio Pharmaceuticals Inc.'s stock is trading above its 50-day and 200-day moving averages of $2.19 and $1.54, respectively. Sign up and read the complimentary report on INO at: http://www.AAAResearchReports.com/INO011614.pdf Sequenom Inc.'s stock surged on Wednesday, closing the day at $2.74, up 6.20% from the previous day's closing price of $2.58. The company's shares vacillated between $2.56 and $2.78 during the trading session. A total of 3.00 million shares were traded, which is above the daily average volume of 2.90 million. The company's shares have gained 28.64% in the previous one month and 5.38% in the last three trading sessions, outperforming the S&P 500, which has gained 4.12% and 0.33% during the respective periods. Additionally, Sequenom Inc.'s stock is trading above its 50-day moving average of $2.34. The free report on SQNM can be downloaded by signing up now at: http://www.AAAResearchReports.com/SQNM011614.pdf Shares in Nektar Therapeutics advanced 0.23% on Wednesday, finishing the day at $13.16, after fluctuating between $12.96 and $13.32 during the trading session. A total of 0.68 million shares were traded, which is below the daily average volume of 0.81 million. The company's shares have surged 24.98% in the previous one month and 37.37% in the last three months, outperforming the S&P 500, which has gained 4.12% and 8.85% during the respective periods. Further, Nektar Therapeutics's stock is trading above its 50-day and 200-day moving averages of $11.29 and $11.15, respectively. A free report on NKTR can be accessed by registering at: http://www.AAAResearchReports.com/NKTR011614.pdf On Wednesday, shares in Discovery Laboratories Inc. surged 4.55%, ending the day at $2.53, after vacillating between $2.43 and $2.56 during the trading session. A total of 1.01 million shares were traded on Wednesday, which is above the daily average volume of 0.72 million. Discovery Laboratories Inc.'s shares have gained 4.12% in the previous three trading sessions and 19.91% in the last one month, outperforming the S&P 500, which has gained 0.33% and 4.12% during the respective periods. Furthermore, the company's stock is trading above its 50-day and 200-day moving averages of $2.21 and $1.93, respectively. Register with AAA Research Reports and download research on DSCO for free at: http://www.AAAResearchReports.com/DSCO011614.pdf EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to making mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. http://www.AAAResearchReports.com/ SOURCE AAA Research Reports Contact: Contact Name: Peter F. Jones - Phone #: +1(646)396-9126, Email ID: firstname.lastname@example.org
Market Technicals Simplified: Inovio Pharma, Sequenom, Nektar Therapeutics, and Discovery Laboratories
Press spacebar to pause and continue. Press esc to stop.